Soon after the broad-spectrum, highly effective antibiotics fluoroquinolones were introduced, their extensive use and misuse in hospitals and communities, as well as in veterinary medicine, have led to the emergence and spread of resistant strains ([@R1],[@R2]). Highly divergent rates of fluoroquinolone resistance in both community-acquired and nosocomial pathogens have been reported worldwide [@R2]. Many factors, including patient characteristics, local epidemiologic factors, antibiotic policies, over-the-counter use (which often leads to inadequate use), lower standard of living in developing countries, lack of information on the prudent use of antibiotics, and use of antibiotics in animal husbandry may contribute to the emergence of quinolone-resistant organisms.

Surveillance is an integral part of controlling resistance, and local and national surveys to identify, monitor, and study the epidemiology of the emergence and spread of resistant isolates are needed [@R3]. To identify national trends and local differences in the epidemiology of quinolone resistance in Greece, we report 1997 ciprofloxacin susceptibility data from the National Electronic System for the Surveillance of Antimicrobial Resistance.

The National Electronic System for the Surveillance of Antimicrobial Resistance was introduced in Greece 3 years ago. Involving 17 hospitals throughout Greece, the system analyzes the routine results of the antibiotic sensitivity tests performed in hospital microbiology laboratories by using WHONET software [@R4].

In our analysis we included 11,097 isolates (4,204 from medical wards, 2,897 from surgical wards, 1,724 from intensive care units \[ICU\], and 2,272 from outpatient departments) (Table 1). We focused on the bacteria most frequently encountered in Greek hospitals (National Electronic System for the Surveillance of Antimicrobial Resistance \[[www.mednet.gr/whonet](http://www.mednet.gr/whonet)\]; N.J. Legakis, Enare Sentry, unpub. data): *Escherichia coli, Klebsiella pneumoniae, Enterobacter species, Pseudomonas aeruginosa, Acinetobacter baumanii, and Staphylococcus aureus. These species are also the most important nosocomial pathogens in most parts of the world in terms of rate of isolation, pathogenicity, and virulence* ([@R5],[@R6])*.*

###### Isolates included in the analysis^a^

                                Type of ward                           
  -- -------------------------- -------------- ------- ------- ------- --------
     *Escherichia coli*         2,100          1,114   94      1,571   4,879
     *Pseudomonas aeruginosa*   672            527     570     195     1,964
     *Staphylococcus aureus*    452            467     318     248     1,485
     *Enterobacter* spp.        396            332     198     142     1,068
     *Klebsiella pneumoniae*    419            224     177     96      916
     *Acinetobacter* spp.       165            233     367     20      785
     All                        4,204          2,897   1,724   2,272   11,097

^a^One isolate per species per patient (the first isolated) is shown. ^b^ICU, intensive care unit.

Isolation and identification were performed by standard methods at the microbiology laboratories of each hospital participating in the network. The susceptibility testing methods were Kirby-Bauer disk diffusion (7 hospitals); Sensititre (Sensititre, Salem, NH) [@R1]; Pasco (Difco, Detroit, MI) [@R8]; and VITEK (Bieux-Merieux Marcy l\'Etoile, France) [@R1]. The actual zone diameters or MICs (not the interpretations of the tests) were entered into WHONET. The chi-square test was used to evaluate differences in resistance rates between types of wards, as well as between clinical specimens. Pearson\'s correlation coefficients were calculated for possible associations between resistance rates and hospital size.

The resistance rate to ciprofloxacin by type of ward, clinical specimen, and bacterial species is shown in [Table 2](#T2){ref-type="table"}. There is a stepwise decrease in the frequency of isolation of ciprofloxacin-resistant isolates (ciprofloxacin resistance in isolates from ICU patients \> isolates from surgical patients \> isolates from medical patients \> isolates from outpatients). These differences were significant (p \<0.01), with the exception of decreases in resistance rates for *E. coli* between surgical wards and ICUs; for *Enterobacter* spp. between medical and surgical wards; for *Acinetobacter* spp. between outpatients, medical, and surgical wards; and for *S. aureus* between medical and surgical wards. Moreover, for *P. aeruginosa,* the resistance rates were significantly higher in medical than in surgical wards (p = 0.00097).

###### Ciprofloxacin resistance by specimen and type of ward^a^

                             Outpatients   Medical   Surgical   ICU                            
  -------------------------- ------------- --------- ---------- -------- ------- ------- ----- ------
  *Escherichia coli*                                                                           
  Urine                      1,191         5.0       1,572      5.5      597     8.5     39    10.2
  Blood                      \-                      195        6.9      14      18.1    5     0.0
  Respiratory                \-                      56         2.1      \-              23    9.0
  Pus                        \-                      33         12.1     203     8.4     11    27.8
  Other                      380           4.5       244        7.5      300     6.5     16    20.0
  All                        1,571         3.7       2,100      5.6      1,114   8.2     94    13.3
  *Salmonella* spp.                                                                            
  Stool                      195           0.7                                                 
  *Klebsiella pneumoniae*                                                                      
  Urine                      62            6.6       254        15.5     85      19.8    28    64.0
  Blood                      \-                      45         11.3     10      9.8     18    72.3
  Respiratory                \-                      62         9.8      12      50.0    90    69.8
  Pus                        \-                      14         50.0     42      19.0    0     0.0
  Other                      34            3.1       44         18.5     79      28.3    41    65.4
  All                        96            5.4       419        15.8     226     23.9    177   67.7
  *Serratia marcences*                                                                         
  All                                                76^c^      7.7^c^                   20    45.2
  *Enterobacter* spp.                                                                          
  Urine                      76            12.0      190        29.7     85      32.0    24    75.4
  Blood                      \-                      37         21.8     13      54.2    24    66.6
  Respiratory                \-                      76         6.3      10      40.2    58    48.6
  Pus                        \-                      22         36.8     138     18.5    27    67.6
  Other                      66            10.8      71         16.9     86      23.3    65    69.0
  All                        142           11.6      396        22.2     332     24.8    198   62.2
  *Pseudomonas aeruginosa*                                                                     
  Urine                      51            31.0      270        44.0     171     40.7    70    79.3
  Blood                      0             0.0       24         20.6     13      46.5    29    75.6
  Respiratory                11            18.2      258        34.4     29      44.6    379   62.9
  Pus                        18            11.3      35         31.6     147     22.6    16    69.5
  Ear                        72            1.7       7          47.3     30      3.7     0     0.0
  Other                      43            18.8      78         26.9     137     25.9    76    66.9
  All                        195           16.7      672        37.5     527     28.2    570   66.4
  *Acinetobacter* spp.                                                                         
  Urine                      \-                      72         62.6     32      65.9    34    94.4
  Blood                      \-                      18         38.7     16      69.0    40    92.3
  Respiratory                \-                      38         49.7     11      100.0   190   91.0
  Pus                        \-                      13         61.8     87      60.1    19    94.8
  Other                      \-                      24         62.5     87      69.1    84    78.9
  All                        20            45.1      165        56.8     233     66.6    367   88.4
  *Staphylococcus aureus*                                                                      
  Urine                      \-                      37         32.9     16      31.0    \-    
  Blood                      \-                      101        51.0     15      67.0    40    62.7
  Respiratory                \-                      123        45.3     28      57.1    221   65.8
  Pus                        104           18.2      88         21.6     272     30.8    14    71.4
  Ear                        52            3.8       \-                  \-              \-    
  Other                      92            10.3      103        25.6     136     31.4    43    67.4
  All                        248           12.8      452        30.5     467     33.0    318   63.6
  MRSA^d^                    40            56.7      140        69.1     176     75.3    375   94.3
  MSSA^e^                    184           1.7       256        12.4     219     6.5     92    4.6

^a^One isolate per patient (the first isolated) is shown. ^b^R, resistant. ^c^Medical and surgical wards combined. ^d^MRSA, methicillin-resistant *S. aureus.* ^e^MSSA, methicillin-sensitive *S. aureus*.

As for clinical specimens, each bacterial species followed a different pattern (Table 2). In medical wards, enterobacterial strains isolated from purulent infections were more often resistant to ciprofloxacin, but this difference was statistically significant only for *K. pneumoniae* (p = 0.012). In surgical wards, blood and respiratory isolates were more often resistant, but this difference was significant only for *Enterobacter* spp. (p = 0.02). On the other hand, ciprofloxacin-resistant *P. aeruginosa* strains were more frequently isolated (p = 0.0021) in medical wards from urine and in surgical wards from urine and blood as opposed to all other specimens (p = 0.0005). No significant differences were observed in the rate of isolation of ciprofloxacin-resistant *A. baumanii* strains among the various clinical specimens. *S. aureus* strains resistant to ciprofloxacin were mostly methicillin-resistant (MRSA) (Table 2). Very low resistance rates were observed in *P. aeruginosa* isolated from ear infections, especially from outpatients.

Approximately 75% of *K. pneumoniae*, 87% of *Enterobacter* spp., 55% of *P. aeruginosa*, 76% of *A. baumanii*, and 75% of MRSA strains were drug resistant to at least three different classes (Table 3). However, 15% of the ciprofloxacin-resistant *E. coli* were resistant only to this antibiotic, and 25% had additional resistance only to cotrimoxazole. Moreover, 48% of ciprofloxacin-resistant but methicillin-sensitive *S. aureus* were resistant only to chloramphenicol.

###### Resistant phenotypes of ciprofloxacin-resistant isolates to other classes of antibiotics^a^

  *Klebsiella pneumoniae*          *Enterobacter* spp            *Escherichia coli*                                      
  -------------------------- ----- -------------------------- -- -------------------- ----- ------- -- ----------- ----- -------
  Phenotype^b^               No.   \%                            Phenotype            No.   \%         Phenotype   No.   \%
  F                          4     3.7                           F                    0     0          F           25    15.1
  DBXF                       9     8.4                           IF                   4     2.5        IDBXF       16    9.6
  IDB F                      16    15.0                          IDB F                7     4.4        IXF         29    17.5
  IDBXF                      64    59.8                          IDBXF                131   82.9       XF          42    25.3
  all other                  14    13.1                          all other            16    10.1       all other   54    32.5
  All                        107   100.0                         All                  158   100.0      All         166   100.0
                                                                                                                         
  *Pseudomonas aeruginosa*         *Acinetobacter baumanii*                                                              
  Phenotype                  No.   \%                            Phenotype            No.   \%                           
  F                          10    7.3                           F                    0     0.0                          
  1DM F                      14    10.2                          SMD X                5     10.0                         
  1DMNF                      23    16.8                          D XF                 15    30.0                         
  1 M F                      40    29.2                          MD XF                23    46.0                         
  all other                  50    36.5                          all other            7     14.0                         
  All                        137   100.0                         All                  50    100.0                        
                                                                                                                         
  *Staphylococcus aureus*                                                                                                
  MRSA                                                           MSSA                                                    
  Phenotype                  No.   \%                            Phenotype            No.   \%                           
  F                          0     0.0                           F                    7     10.3                         
  OG E F                     23    11.3                          E F                  9     13.2                         
  OG ECF                     44    21.7                          CF                   33    48.5                         
  OGXECF                     84    41.4                                                                                  
  all other                  52    25.6                          all other            19    27.9                         
  All                        203   100.0                         All                  68    100.0                        

^a^All wards, intensive care units isolates are not included. ^b^1, piperacillin; B, tobramycin; C, chloramphenicol; D, ceftazidime; E, erythromycin; F, ciprofloxacin; G, gentamicin; I, cefoxitin; M, amikacin; N, imipenem; O, oxacillin; S, amoxicillin/sulbactam; X, cotrimoxazole; MRSA, methicillin-resistant *S. aureus;* MSSA, methicillin-sensitive *S. aureus*.

When we plotted resistance rates to ciprofloxacin against the number of beds in each hospital, we found no correlation ([Figure](#F1){ref-type="fig"}). The rate of isolation of ciprofloxacin-resistant isolates varied greatly by hospital for all species examined: from 1% to 15% for *E. coli*, 1% to 23% for *K. pneumoniae*, 1% to 33% for *Enterobacter* spp., 11% to 33% for *P. aeruginosa*, 29% to 73% for *A. baumanii*, and 11% to 48% for *S. aureus.* Ciprofloxacin resistance was observed in hospitals throughout Greece.

![Resistance rates to ciprofloxavin in each hospital by number of beds and geographic area of the hospital. Only hospitals with more than 20 isolates are included. (Isolates from all wards but not intensive care units.)](99-0325-F){#F1}

In Europe and North America, a striking difference in the incidence of bacterial resistance to quinolones has been observed between nosocomial and community-acquired infections; resistance is only rarely encountered among the latter ([@R2],[@R7]). The incidence of resistance to fluoroquinolones in bacteria isolated from hospital-acquired infections varies among bacterial species, clinical settings, and countries and may be related to local epidemic spread of a few clones [@R2]. The highest incidence of resistance is among *P. aeruginosa, Acinetobacter* spp., *Serratia marcescens,* and particularly MRSA strains [@R8]. Our results place Greece among the countries with high resistance levels to quinolones. Although quinolones are among the antibiotics restricted by the Greek Ministry of Health and Welfare, the mean national level of quinolone resistance has increased in most bacterial species during the last 5 years [@R9].

The 3.7% quinolone resistance rate among *E. coli* isolated from outpatients is almost double that in other industrialized countries [@R2]. This high rate may be due to the use of quinolones, and especially norfloxacin, as a first-line antibiotic in Greece to treat uncomplicated urinary tract infections in the outpatient setting. Free access to fluoroquinolones has also been incriminated in increased quinolone resistance in industrialized and developing countries ([@R10],[@R11]). The low rate of quinolone resistance in salmonellas, compared with other countries ([@R12],[@R13]), may be due to infrequent use of quinolones in farm animals in Greece. Among *Enterobacteriaceae,* quinolone resistance seems to be higher in *K. pneumoniae* and *Enterobacter* spp. than in *S. marcescens*.

The high level of resistance in ICUs was expected since ICUs are well-known focuses of antimicrobial resistance [@R14]. Hospitalization in ICUs was an independent risk factor for acquiring infection by multidrug-resistant strains in Greece [@R15]. Moreover, ICU patients are often colonized with endemic, multidrug-resistant strains, which often spread to other wards [@R16].

We found higher rates of isolation of quinolone-resistant strains of some species in the surgical wards than in medical wards. Patients at high risk for a resistant nosocomial infection (e.g., cancer patients, immunosupressed patients) are usually in medical wards. High resistance in the surgical wards could be the result of nursing practices or unnecessary prophylactic administration of antibiotics, both of which should be further evaluated.

Most quinolone-resistant strains in Greece are also resistant to other clinically relevant antibiotics. The possible clinical and epidemiologic importance of the newly described multidrug efflux pumps in multidrug resistance, mainly in *P. aeruginosa,* is under investigation worldwide [@R17]. Moreover, the marginal susceptibility of *S. aureus* to quinolones and the ease with which mutations affecting susceptibility can occur in this species contribute to the observed high rates of quinolone resistance. MRSA strains are no more likely to develop resistance to quinolones than other staphylococci [@R8]. In any case, the favorable accumulation of different traits in quinolone-resistant strains or, alternatively, the favorable potential for mutation to quinolone resistance in multidrug-resistant strains has not been proved. Epidemiologic parameters, and more specifically the sequential introduction of various antibiotic classes in most of the world and in Greek hospitals, could explain multidrug resistance. The extensive aminoglycoside and beta-lactamase use in the 1980s is responsible for the high prevalence of multidrug-resistant plasmids and transposons found in the nosocomial strains of various bacterial genera in Greek hospitals ([@R18]-[@R20]). The strains harboring these plasmids can survive in the hospital environment and become the best candidates for selection of resistant mutants under the pressure of quinolones.

That quinolone-resistant strains are found in hospitals in all parts of Greece and resistance is not associated with the size of the hospital or its geographic area are consistent with the high prescription rate for quinolones. However, the isolation rate of resistant strains varied considerably by hospital, perhaps because of local epidemiologic factors (e.g., prescribing or nursing habits) or possible (epidemic) spread of strains among patients.

This study has limitations. First, it is based on routine data generated in the microbiology laboratories of participating hospitals. Sometimes different antibiotics are tested in each hospital, which limits the possibility for interhospital comparisons. Moreover, different methods for susceptibility testing are used in each hospital. Data such as antibiotic consumption or days of hospitalization are not available since they are not included as information in the WHONET software and they are difficult and time-consuming to collect routinely.

Quinolone use is a well-proven independent risk factor for resistance ([@R21],[@R22]). Nevertheless, local differences indicate that other epidemiologic parameters should be further evaluated.
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